PureTech Health plc

BATS-CHIXE:PRTCL Stock Report

Market Cap: UK£405.6m

PureTech Health Valuation

Is PRTCL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PRTCL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PRTCL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PRTCL's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PRTCL?

Key metric: As PRTCL barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for PRTCL. This is calculated by dividing PRTCL's market cap by their current book value.
What is PRTCL's PB Ratio?
PB Ratio1.6x
BookUS$315.87m
Market CapUS$514.10m

Price to Book Ratio vs Peers

How does PRTCL's PB Ratio compare to its peers?

The above table shows the PB ratio for PRTCL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average45.5x
OXB Oxford Biomedica
6.8x93.2%UK£447.8m
BVXP Bioventix
16.4xn/aUK£197.0m
FARN Faron Pharmaceuticals Oy
156.9x17.3%UK£180.5m
GNS Genus
2x37.7%UK£1.1b
PRTCL PureTech Health
1.6x-13.0%UK£405.6m

Price-To-Book vs Peers: PRTCL is good value based on its Price-To-Book Ratio (1.6x) compared to the peer average (45.5x).

Price to Book Ratio vs Industry

How does PRTCL's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
BDRX Biodexa Pharmaceuticals
0.5xn/aUS$4.42m
LLAI LungLife AI
0.4x101.0%US$3.50m
VAL ValiRx
0.6xn/aUS$2.81m
No more companies available in this PB range
No. of Companies7PB02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: PRTCL is good value based on its Price-To-Book Ratio (1.6x) compared to the UK Biotechs industry average (2.8x).

Price to Book Ratio vs Fair Ratio

What is PRTCL's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PRTCL PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate PRTCL's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PRTCL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£1.70
UK£5.59
+229.1%
18.6%UK£6.64UK£4.55n/a2
Nov ’25UK£1.57
UK£5.59
+256.8%
18.6%UK£6.64UK£4.55n/a2
Oct ’25UK£1.41
UK£5.48
+287.4%
17.6%UK£6.44UK£4.51n/a2
Sep ’25UK£1.63
UK£5.40
+231.4%
15.7%UK£6.25UK£4.56n/a2
Aug ’25UK£1.67
UK£5.42
+224.0%
16.2%UK£6.30UK£4.55n/a2
Jul ’25UK£1.82
UK£5.42
+197.7%
16.2%UK£6.30UK£4.55n/a2
May ’25UK£2.14
UK£4.93
+130.1%
26.6%UK£6.24UK£3.61n/a2
Apr ’25UK£2.24
UK£4.67
+108.3%
23.8%UK£6.20UK£3.60n/a3
Mar ’25UK£2.04
UK£4.68
+129.5%
23.9%UK£6.23UK£3.62n/a3
Feb ’25UK£1.95
UK£5.70
+191.9%
45.0%UK£9.30UK£3.60n/a3
Jan ’25UK£1.96
UK£5.71
+191.5%
44.9%UK£9.31UK£3.61n/a3
Dec ’24UK£1.51
UK£5.69
+276.8%
45.0%UK£9.30UK£3.63n/a3
Nov ’24UK£1.51
UK£5.90
+291.3%
40.6%UK£9.28UK£4.04UK£1.573
Oct ’24UK£1.82
UK£5.78
+217.7%
42.6%UK£9.26UK£3.88UK£1.413
Sep ’24UK£1.99
UK£5.78
+190.0%
42.6%UK£9.26UK£3.88UK£1.633
Aug ’24UK£2.23
UK£5.87
+163.8%
41.3%UK£9.30UK£4.09UK£1.673
Jul ’24UK£2.19
UK£5.87
+168.0%
41.3%UK£9.30UK£4.09UK£1.823
Jun ’24UK£2.19
UK£5.96
+172.3%
40.3%UK£9.36UK£4.20UK£2.333
May ’24UK£2.08
UK£5.96
+186.7%
40.3%UK£9.36UK£4.20UK£2.143
Apr ’24UK£2.22
UK£6.35
+186.8%
33.2%UK£9.33UK£4.71UK£2.243
Mar ’24UK£2.18
UK£5.98
+174.2%
39.4%UK£9.30UK£4.12UK£2.043
Feb ’24UK£2.47
UK£5.98
+142.0%
39.4%UK£9.30UK£4.12UK£1.953
Jan ’24UK£2.66
UK£6.03
+127.1%
38.3%UK£9.28UK£4.20UK£1.963
Dec ’23UK£2.85
UK£6.54
+129.6%
31.1%UK£9.36UK£4.64UK£1.513
Nov ’23UK£2.42
UK£6.78
+180.9%
26.9%UK£9.29UK£4.99UK£1.513

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Formycon

€857.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.65

7D

3.6%

1Y

-24.5%

hVIVO

UK£144.6m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.21

7D

-3.8%

1Y

4.9%

Laboratorios Farmaceuticos Rovi

€3.3b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€64.00

7D

3.6%

1Y

15.7%